STAGE IVA BLADDER CANCER AJCC V8
Clinical trials for STAGE IVA BLADDER CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IVA BLADDER CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IVA BLADDER CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Bladder cancer drug combo trial pulled before it even started
Disease control TerminatedThis trial was designed to test two drugs—erdafitinib and atezolizumab—for people with muscle invasive bladder cancer who cannot take the standard chemotherapy drug cisplatin. Erdafitinib targets a specific gene change that can drive cancer growth, while atezolizumab helps the im…
Matched conditions: STAGE IVA BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 23, 2026 12:00 UTC
-
New hope for bladder cancer patients who Can't take chemo
Disease control OngoingThis study tests whether combining radiation therapy with immunotherapy drugs (durvalumab with or without tremelimumab) can help people with advanced bladder cancer who cannot or will not have chemotherapy. The trial includes 13 participants with cancer that has spread or cannot …
Matched conditions: STAGE IVA BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 23, 2026 11:59 UTC
-
Immunotherapy-Chemo combo targets tough neuroendocrine cancers
Disease control OngoingThis early-phase trial tests whether adding the immunotherapy drug pembrolizumab to standard platinum-based chemotherapy can help people with rare, aggressive small cell or neuroendocrine cancers of the bladder or prostate. The study includes 15 participants whose cancer has spre…
Matched conditions: STAGE IVA BLADDER CANCER AJCC V8
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 22, 2026 11:58 UTC
-
Can a simple test predict who will respond to immunotherapy?
Knowledge-focused OngoingThis study looks at whether certain gene mutations (ARID1A and KDM6A) and a protein called CXCL13 in tumors can help predict if the immunotherapy drug nivolumab will work for people with advanced bladder cancer that has spread. Only 6 participants with these specific gene changes…
Matched conditions: STAGE IVA BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 17, 2026 12:08 UTC